Intranasal Stem Cell Therapy Shows Early Promise for Newborn Brain Injury

Published by UMC Utrecht

In the PASSIoN safety study at UMC Utrecht, ten newborns with perinatal stroke received a single dose of mesenchymal stem cells delivered as nasal drops within a week of birth. Over two years, no treatment-related side effects were reported and developmental outcomes were better than expected, including earlier walking and a lower rate of mild cerebral palsy than historical controls, with no epilepsy or vision problems observed. The team notes this study assessed safety, not efficacy, and plans a larger randomized trial, iSTOP-CP, in 2026 to confirm benefit.

Read the full article on UMC Utrecht:

👉 Stem cell treatment offers hope for newborns with brain damage

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.